Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 19;13(1):e0191243.
doi: 10.1371/journal.pone.0191243. eCollection 2018.

The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology

Affiliations

The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology

Mohsen Sadatsafavi et al. PLoS One. .

Abstract

Background: There is minimal evidence on the extent to which the occurrence of a severe acute exacerbation of COPD that results in hospitalization affects the subsequent disease course. Previous studies on this topic did not generate causally-interpretable estimates. Our aim was to use corrected methodology to update previously reported estimates of the associations between previous and future exacerbations in these patients.

Methods: Using administrative health data in British Columbia, Canada (1997-2012), we constructed a cohort of patients with at least one severe exacerbation, defined as an episode of inpatient care with the main diagnosis of COPD based on international classification of diseases (ICD) codes. We applied a random-effects 'joint frailty' survival model that is particularly developed for the analysis of recurrent events in the presence of competing risk of death and heterogeneity among individuals in their rate of events. Previous severe exacerbations entered the model as dummy-coded time-dependent covariates, and the model was adjusted for several observable patient and disease characteristics.

Results: 35,994 individuals (mean age at baseline 73.7, 49.8% female, average follow-up 3.21 years) contributed 34,271 severe exacerbations during follow-up. The first event was associated with a hazard ratio (HR) of 1.75 (95%CI 1.69-1.82) for the risk of future severe exacerbations. This risk decreased to HR = 1.36 (95%CI 1.30-1.42) for the second event and to 1.18 (95%CI 1.12-1.25) for the third event. The first two severe exacerbations that occurred during follow-up were also significantly associated with increased risk of all-cause mortality. There was substantial heterogeneity in the individual-specific rate of severe exacerbations. Even after adjusting for observable characteristics, individuals in the 97.5th percentile of exacerbation rate had 5.6 times higher rate of severe exacerbations than those in the 2.5th percentile.

Conclusions: Using robust statistical methodology that controlled for heterogeneity in exacerbation rates among individuals, we demonstrated potential causal associations among past and future severe exacerbations, albeit the magnitude of association was noticeably lower than previously reported. The prevention of severe exacerbations has the potential to modify the disease trajectory.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: This study was funded by an Operating Grant from the Canadian Institutes of Health Research (CIHR, #142238) and funds from the Canadian Respiratory Research Network (CRRN); CRRN is supported by grants from CIHR - Institute of Circulatory and Respiratory Health; Canadian Lung Association (CLA)/Canadian Thoracic Society (CTS); British Columbia Lung Association; and Industry Partners Boehringer-Ingelheim Canada Ltd, AstraZeneca Canada Inc., and Novartis Canada Ltd. Funding for training of graduate students and new investigators within the network was supported by the above funding Sponsors and as well by GlaxoSmithKline Inc. None of the commercial sources (Boehringer-Ingelheim Canada Ltd, AstraZeneca Canada Inc., Novartis Canada Ltd and GlaxoSmithKline Inc) were in any capacity involved in the present research and their contribution was made to the overall funding of the Canadian Respiratory Research Network not any specific projects. Mohsen Sadatsafavi is supported by a New Investigator Award from CIHR and a Scholar Award from Michael Smith Foundation for Health Research. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript. Mohsen Sadatsafavi has served on the advisory board of Boehringer-Ingelheim Canada Ltd for a completely independent activity and has received a small honorarium as a result. He has received funding into his research account directly paid to the University of British Columbia from AstraZeneca Canada Inc. J Mark FitzGerald has served on advisory boards, and has received honorarium from Boehringer-Ingelheim Canada Ltd, AstraZeneca Canada Inc., Novartis Canada Ltd and GlaxoSmithKline Inc. The activities of the advisory boards were not related to the present study. These do not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Regression coefficients relating the occurrence of each follow-up severe exacerbations to subsequent severe exacerbations (green circles) or death (black squares).
Footnote: Regression coefficients for all variables are provided in S2 Table. For each exacerbation, the reference (baseline) hazard for the reported HR is the period between the immediately previous and the current exacerbation.
Fig 2
Fig 2. Individualized hazard ratios* of severe exacerbations after removing the effects of observed patient characteristics†.
Footnote: * Individual-specific HRs represent the tendency of individuals to exacerbate or die that exceeds the effects of the independent variables included in the model. † 0.8% of individuals had HRs of greater than 5 and were not shown in this graph.

Similar articles

Cited by

References

    1. Aaron SD. Management and prevention of exacerbations of COPD. BMJ. 2014;349: g5237 doi: 10.1136/bmj.g5237 - DOI - PubMed
    1. Canadian Thoracic Society. The Human and Economic Burden of COPD [Internet]. 2010. http://www.respiratoryguidelines.ca/the-human-and-economic-burden-of-cop...
    1. Suissa S, Dell’aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67: 957–963. doi: 10.1136/thoraxjnl-2011-201518 - DOI - PMC - PubMed
    1. Sadatsafavi M, Fitzgerald JM. Heterogeneity’s ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations. Thorax. 2014; doi: 10.1136/thoraxjnl-2013-205061 - DOI - PMC - PubMed
    1. Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1: 255–273. - PubMed

Publication types